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A B S T R A C T
Aims: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic
syndrome (MS) subdivided according to the presence or not of diabetes mellitus.
Methods: We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics
(14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which
relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,20-azino-bis(3-
ethylbenzthiazoline sulfonic acid) to the radical ABTS+.
Results: In the group of MS subjects a signiﬁcant decrease in TAS (p < 0.05) in comparison with normal
controls was evident. This difference was present between normal subjects and nondiabetic subjects
with MS (p < 0.001) but not between normal and diabetic subjects with MS. Examining the linear
regression among TAS, age, anthropometric proﬁle, blood pressure values and glycometabolic pattern,
conﬂicting data were found.
Conclusions: Although we know that TAS includes several enzymatic and non enzymatic antioxidants,
we retain that the difference observed in the two subgroups of subjects with MS must be looked in
particular into two pathophysiological aspects regarding bilirubin and uric acid.
 2014 Diabetes India. Published by Elsevier Ltd. All rights reserved.
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Up to now several antioxidants, including retinol, retinyl esters,
carotenoids (b-carotene, a-carotene, b-cryptoxanthin, lycopene
and zeaxanthin/lutein), vitamin E and vitamin C, have been
examined in patients with metabolic syndrome (MS) [1,2] while
previously observational studies have regarded the levels of serum
carotenoids in MS [3] and in type 2 diabetes mellitus (DM) [4].
Conversely, many research have looked at the effects of long-term
antioxidant supplementation in adults with risk of MS [5] and in
type 2 diabetic subjects [6] with contrasting results.
The antioxidant defence includes the hydrosoluble antioxidants
such as uric acid, vitamin C, total proteins and albumin, the
liposoluble antioxidants, as bilirubin and vitamin E, and the
enzymatic antioxidants such as superoxide dismutase, catalase,
glutathione peroxidase. In the clinical practice the antioxidant
status may be altogether investigated as total antioxidant capacity
(TAC), ferric reducing ability of plasma (FRAP), total antioxidant
activity (TAA), total radical-trapping antioxidant parameter (TRAP)
and total antioxidant status (TAS).* Corresponding author. Tel.: +39 091 6554406; fax: +39 091 6554535.
http://dx.doi.org/10.1016/j.dsx.2014.04.013
1871-4021/ 2014 Diabetes India. Published by Elsevier Ltd. All rights reserved.We know that MS represents a multifactorial status character-
ized by different combinations of three or more of the following
clinical conditions: diabetes mellitus, arterial hypertension,
dyslipidemia and visceral obesity, and in this syndrome as well
as in its principal features the behavior of total antioxidant status
has been examined. In many papers [7–12] that have regarded MS,
this parameter has been found reduced. In the paper of Sebekova
et al. [13] regarding the association of MS risk factors in health
omnivores (traditional western mixed diet) and vegetarians, FRAP
was different between the two groups, after the subdivision
according to the risk factor. In fact, while in omnivores the trend of
antioxidant status changed in relation to the number of risk factors,
although not signiﬁcantly, that did not happen in the vegetarian
group.
There are more information about antioxidant status in the
principal components of MS. In morbid obesity [14] and in
overweight subjects without MS [12] no statistical difference was
observed in total antioxidant status. In type 2 DM the antioxidant
status resulted reduced in some papers [15–17] although Savu
et al. [18] observed its increase in comparison with control
subjects. These authors [18] in subjects with uncomplicated type 2
DM also found a signiﬁcant increase in plasma concentrations of uric
acid and copper and in ceruloplasmin activity. As it is known, copper
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enzyme, but at the same time it may exert pro-oxidative effects, as
well as ceruloplasmin. The antioxidant status signiﬁcantly improved
in morbidly obeses with type 2 DM undergoing bariatric surgery
[19]. This parameter, according to some authors, clearly distin-
guished diabetic subjects with and without proteinuria even if
others did not observe this distinction [20]. In type 2 diabetic
subjects the plasma total antioxidant status was also related to the
glycometabolic control and to vascular complications [15]. Lapolla
et al. [21] noted signiﬁcantly lower levels of TRAP in type 2 diabetics
with peripheral artery disease (PAD) in comparison with type 2
diabetics without PAD. In arterial hypertension some authors have
described a TAS decrease [22–24]; this ﬁnding has been noted also in
subjects with prehypertension [22]. In hypertensives with metabolic
syndrome TAS was reduced in comparison with hypertensives
without MS [25]. The total antioxidant status was also negatively
correlated with insulin resistance in hypercholesterolemic patients
[26] while the data regarding this parameter after lipid-lowering
therapy seem to be controversial; in fact, while bezaﬁbrate reduces
the plasma total antioxidant activity [27] and atorvastatin rises this
parameter [28], simvastatin seems to act on this parameter with
different effects [29,30].
Considering this preamble our aim was to examine the TAS in
MS subjects according to the presence or not of DM.
2. Subjects and methods
We enrolled 106 consecutive subjects with MS (61 men and 45
women), deﬁned following the International Diabetes Federation
(IDF) criteria [31]. Subsequently MS subjects were subdivided in
diabetics (29 men and 14 women) and in nondiabetics (32 men and
31 women).
In the entire group of MS subjects mean age was 53.5  8.9
years, BMI was 32.21  4.53, waist circumference was
106.7  11.2 cm, SBP and DBP were respectively 132.1  16.3 and
81.2  9.9 mmHg, fasting blood glucose was 114.3  44.3 mg/dl, total
cholesterol was 213.9  53.0 mg/dl, HDL-chol was 40.4  10.8 mg/dl,
LDL-chol was 133.2  46.5 mg/dl and triglycerides were
220.2  147.8 mg/dl. In the subgroup of diabetic MS subjects mean
age was 58.9  6.0 years, BMI was 33.2  5.0, waist circumference
was 114.4  11.7 cm, SBP and DBP were respectively 136.0  20.5
and 79.6  11.4 mmHg, fasting blood glucose was 147.5  54.2 mg/
dl, total cholesterol was 193.1  53.1 mg/dl, HDL-chol was
41.4  12.8 mg/dl, LDL-chol was 112.8  39.7 mg/dl and triglycerides
were 204.2  150.9 mg/dl. In the subgroup of nondiabetic MS
subjects mean age was 49.7  8.6 years, BMI was 31.5  4.2, waist
circumference was 102.8  8.8 cm, SBP and DBP were respectively
130.0  13.3 and 82.2  8.9 mmHg, fasting blood glucose was
92.2  10.3 mg/dl, total cholesterol was 228.0  48.3 mg/dl, HDL-
chol was 39.7  9.3 mg/dl, LDL-chol was 147.9  45.8 mg/dl and
triglycerides were 231.0  145.9 mg/dl.
The study was approved by Ethical Commettee and each subject
gave informed consent.
Blood samples were collected by venous puncture from the
antecubital vein of each subject and immediately transferred to glass
tube anticoagulated with EDTA-K3 to evaluate TAS. Total antioxi-
dant status was obtained using an Assay kit (Calbiochem, La Jolla,
USA) which relies on the ability of plasma antioxidant substances to
inhibit the oxidation of 2,20-azino-bis(3-ethylbenzthiazoline sul-
fonic acid) (ABTS) to the radical cation ABTS+ by a peroxidase [32].
The radical concentration was measured by spectrophotometry.
The same parameter was also examined in a group of 54 normal
subjects (35 men and 19 women, mean age 41.3  7.4 years)
recruited from the hospital staff members.
The values were expressed as means  s.d.; the differences
between subjects with metabolic syndrome, diabetics and nondia-betics, and normal controls were evaluated using Student’s t test for
unpaired data; the correlations were performed employing the linear
regression test. The null hypothesis was rejected for p values less than
0.05.
3. Results
The obtained data show that, in comparison with normal
subjects, in the whole group of MS subjects was evident a decrease
in TAS (N = 0.986  0.238; MS = 0.882  0.223, p < 0.05). This datum
was also present between normal subjects and nondiabetic subjects
with MS (N = 0.986  0.238; NDMS = 0.809  0.211, p < 0.001) but
not between normal subjects and diabetic subjects with MS
(N = 0.986  0.238; DMS = 0.987  0.199). The total antioxidant
status was also signiﬁcantly different (p < 0.001) between diabetic
and nondiabetic MS subjects. Examining the linear regression
between TAS, age, anthropometric proﬁle, blood pressure values
and glycometabolic pattern, we found in the whole group of MS
subjects a positive correlation between TAS and age (r = 0.251,
p < 0.01), TAS and waist circumference (r = 0.386, p < 0.001), TAS and
fasting glucose level (r = 0.250, p < 0.05), and also between TAS and
triglycerides (r = 0.238, p < 0.05). In the subgroup of nondiabetic MS
subjects we noted a positive correlation between TAS and waist
circumference (r = 0.310, p < 0.05) and a negative correlation
between TAS and HDL-cholesterol (r = 0.290, p < 0.05), while in
the subgroup of diabetic subjects with MS we observed a positive
correlation between TAS and diastolic blood pressure (r = 0.418,
p < 0.05) and between TAS and total cholesterol (r = 0.388, p < 0.05),
TAS and LDL-cholesterol (r = 0.400, p < 0.05) and also between TAS
and triglycerides (r = 0.408, p < 0.01).
4. Discussion
The reduction of total antioxidant status observed in the entire
group of MS subjects conﬁrms almost quite what has been
observed previously in MS and also in its principal components,
although the datum that deserves to be underlined regards the
different behavior observed in diabetic and nondiabetic subjects
with MS. Even if in diabetes mellitus the observations regarding
the TAS are not univocal [15–18], we think that this distinction
needs speciﬁc considerations. We know that the evaluation of total
antioxidant status includes enzymatic and non-enzymatic anti-
oxidants and it is not possible to exclude that the difference
observed in these two subgroups of MS subjects must be looked
especially into two pathophysiological aspects concerning the
levels of bilirubin and uric acid.
Some data, in fact, have underlined the protective role played by
bilirubin in metabolic syndrome [33,34], but we do not dispose of
its values in the two subgroups. As it is known, bilirubin acts as
antioxidant irrespective of whether it is unconjugated, conjugated
or albumin bound and at the same time we know that in diabetes
mellitus is present an erythrocyte mechanical fragility, signiﬁ-
cantly correlated to fasting plasma glucose and to lipid peroxida-
tion [35], that, inducing intravascular hemolysis, theoretically may
induce a bilirubin increase.
The other pathophysiological aspect regards the role of uric acid
in metabolic syndrome. A relationship between hyperuricemia and
various MS components (hypertension, obesity, diabetes mellitus)
has been demonstrated [36–39] and serum uric acid levels seem to
be clearly associated with the prevalence of MS [36] and the
incidence of DM [40]. In addition, in type 2 diabetic subjects
hyperuricemia is correlated with the vascular complications, such
as retinopathy, cerebrovascular and coronary artery diseases, and
nephropathy [41].
In the last years a paradoxal role of uric acid has been
hypothesized as it could act as an antioxidant in plasma and
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[40,42]; it is not possible to exclude that MS subjects with type 2
diabetes mellitus were hyperuricemic but we know the serum uric
acid levels of a small group of MS subjects (data not shown).
The study of the linear regression among TAS, age, anthropo-
metric proﬁle, blood pressure values and glycometabolic pattern
seems to be controversial and then some statistical correlation
may be fortuitous and biologically inexplicable. Although in the
entire group of MS subjects we found a positive correlation
between TAS and age, in Attica study [22] this statistical
correlation was negative. Regarding the positive correlation
observed among TAS, total cholesterol, LDL-cholesterol and
triglycerides in the subgroup of diabetics with MS, and the
negative correlation between TAS and HDL-cholesterol in non-
diabetics with MS, we have few information; however, in Attica
study [22] no signiﬁcant correlation was observed between TAS
and plasma lipids, and other authors noted only a negative
correlation between TAS and total cholesterol level. The positive
correlation among TAS, waist circumference, blood glucose levels,
and diastolic blood pressure seems to be occasional. At this regard,
in the paper of Demircan [8] TAS was negatively correlated to the
blood pressure values; no signiﬁcant correlation was whereas
found between TAS and blood glucose levels in the Attica study
[22] while a negative correlation between these two parameters
was reported by other authors [15].
Two are the consideration that can be drawn from these results
concerning the group of MS subjects subdivided according to the
presence or not of diabetes mellitus. The ﬁrst regards the datum
that in the subgroup of diabetics with MS the total antioxidant
status was similar to that found in normal controls; the second
regards the probable ineffectiveness of any speciﬁc oral supple-
mentation in these subjects.
At the same time in order to conﬁrm the alteration of oxidative
status accompanying the MS, in the entire group of MS (r = 0.268,
p < 0.055) and in the subgroup of MS diabetics (r = 0.375,
p < 0.0131) we found a signiﬁcant and positive correlation
between TAS and lipid peroxidation, expressed as thiobarbituric
acid reactive substances (TBARS).
The evaluation of TAS may be an useful marker in the
monitoring of MS, considering that its trend may be inﬂuenced
by the use of several drugs, such as oral hypoglycemic agents [43],
lipid lowering drugs [28,29] and antihypertensive agents [44], able
to inﬂuence this parameter of oxidative status.
This research, conﬁrming the literature data regarding the
behavior of TAS in subjects with MS, clearly underlines how its
trend is dependent on the presence of DM and it is possible to
suppose that this datum could be inﬂuenced by non-enzymatic
factors not evaluated in this preliminary study. At the same
time, this ﬁnding needs further investigation thus, up to now,
many research have regarded the use of the antioxidant
supplementation in type 2 diabetic subjects with conﬂicting
results. In fact, several studies have demonstrated that in diabetic
subjects vitamin E supplementation improves blood glucose
levels [45], and oxidative status parameters [46]. As well as the
combination of vitamin E and C reduced HbA1c and increased the
activity of some antioxidant enzymes [47]. In diabetic obese
subjects, the supplementation with vitamin E and omega-3 fatty
acids, besides increasing total antioxidant capacity and antioxi-
dant enzymes activity, reduced lipid peroxidation and protein
carbonylation [48]. Also the oral administration of a-lipoic acid
reduces lipid peroxidation and improves glycometabolic control
[49]. On the other hand, the association of vitamin E and A had no
beneﬁcial effects on cardiovascular events and mortality in type 2
diabetics [50].Conﬂict of interest
No conﬂict of interest
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